Statement of Principles concerning photocontact dermatitis (Reasonable Hypothesis) (No. 82 of 2020)

This Statement of Principles (No. 82 of 2020) is a legislative instrument made by the Repatriation Medical Authority (RMA) under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA). It sets out the medical‑scientific factors necessary to establish a reasonable hypothesis that photocontact dermatitis, or death from that condition, is connected to relevant service rendered by veterans, members of Peacekeeping Forces, members of the Forces under the VEA, or members under the Military Rehabilitation and Compensation Act 2004 (MRCA).

The instrument repeals and replaces the earlier Statement of Principles concerning photocontact dermatitis (No. 108 of 2011) and applies to claims made under section 120A of the VEA or section 338 of the MRCA. It commenced on 30 November 2020. The instrument does not itself award compensation or impose government expenditure; rather, it acts as a binding rule of evidence for decision‑makers at the Repatriation Commission, the Veterans’ Review Board, and reviewing tribunals. If at least one factor in section 9 is present and is related to the person’s relevant service, a reasonable hypothesis is raised, and the decision‑maker must accept the connection unless disproved beyond reasonable doubt (under the VEA’s section 120 standard).

The factors themselves are temporally narrow: for phototoxic contact dermatitis, the affected skin must have been exposed to light in the presence of a topically‑applied phototoxic agent within the 48 hours before clinical onset or clinical worsening. For photoallergic contact dermatitis, the window is five days. The only non‑exposure factor is “inability to obtain appropriate clinical management”, which can apply to both onset and worsening. The instrument also cross‑references other Statements of Principles when a factor refers to a separate injury or disease covered by another such instrument (section 11). In summary, this SoP mechanically limits the range of factual scenarios that can sustain a claim for photocontact dermatitis, while still preserving a route through clinical‑management failures.

The central condition is photocontact dermatitis, defined in subsection 7(2) as inflammation of skin from exposure to light in the presence of a phototoxic agent or photoallergen that has been applied to the same area of skin. It includes phototoxic contact dermatitis and photoallergic contact dermatitis, but expressly excludes allergic contact dermatitis, irritant contact dermatitis, phototoxic contact dermatitis due to systemic administration of a phototoxicant, and systemic allergic dermatitis. The ICD‑10‑AM code is L56.2, but the definition in the instrument prevails over the code for interpretation.

“Light” is defined broadly in the Schedule 1 Dictionary as sunlight, and natural and artificial sources of ultraviolet and visible light, including exposure through glass windows, operating theatre lights, or therapy lamps. This expansive definition means indoor or filtered light can be sufficient, which widens the potential claim scenarios beyond direct outdoor sunlight.

Two classes of agents are distinguished. A “phototoxic agent” is a topical substance that, when present in skin exposed to light, produces direct tissue injury and inflammation. Examples given include coal tar cream, fluorouracil cream, fig tree sap, lime or lemon juice, cosmetic products, and PUVA or photodynamic topical therapy. A “photoallergen” is a substance that, when present in the skin and exposed to light, is capable of producing an immune response and inflammation. Examples include UV absorbers in sunscreens and cosmetics (octocrylene, benzophenones, cinnamates, para‑aminobenzoic acid derivatives), topical non‑steroidal anti‑inflammatory drugs (ketoprofen, piroxicam), fragrance chemicals (methyl coumarins, musk ambrette), and antimicrobials (fentichlor, hexachlorophene). The distinction matters because the time windows differ (48 hours for phototoxic, five days for photoallergic) and because the underlying mechanism (direct toxicity versus immune sensitisation) affects the required evidence.

“Relevant service” is defined by reference to the VEA and MRCA categories: operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA. This is a closed list; ordinary peacetime defence service that does not fit into one of these categories is not covered. The instrument also defines “terminal event” as the proximate or ultimate cause of death, including pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function, to accommodate death‑from‑photocontact dermatitis claims.

The instrument operates on the “reasonable hypothesis” standard, not the higher “balance of probabilities” standard. The RMA states in section 8 that there is sound medical‑scientific evidence indicating that photocontact dermatitis can be related to relevant service. This is the basis for the factors.

The primary affected group is claimants under the VEA and MRCA who suffer from photocontact dermatitis or who die from it. This includes veterans who have rendered operational, peacekeeping, hazardous, or British nuclear test defence service under the VEA, and members of the Australian Defence Force who have rendered warlike or non‑warlike service under the MRCA. The instrument does not apply to general civilian claims or to workers’ compensation schemes; its scope is confined to the military compensation and veterans’ entitlement systems.

Decision‑makers at the Repatriation Commission are directly affected because they must apply this instrument when determining liability. They cannot accept a reasonable hypothesis that relies on facts outside the factor list in section 9. The Veterans’ Review Board and the Administrative Appeals Tribunal also must apply the instrument on review. Medical practitioners who provide reports for compensation claims are indirectly affected: they need to understand the definitions (e.g., what counts as a phototoxic agent) and the time windows, because their clinical opinions will be assessed against the SoP. If a medical report does not specify that the agent was topically applied or that exposure occurred within the relevant hours or days, the claim may fail even if the dermatitis is genuinely service‑related.

Defence organisations may be affected where the “inability to obtain appropriate clinical management” factor is raised. If a claimant can show that the military medical system failed to provide appropriate management for photocontact dermatitis, that factor alone can ground a reasonable hypothesis (factor 9(5)). This creates an indirect incentive for Defence to ensure that clinical management (e.g., avoidance of light, topical treatments, removal of the causative agent) is provided in a timely and effective manner.

Manufacturers and suppliers of topical products such as sunscreens, cosmetics, topical NSAIDs, and coal tar preparations are not directly regulated by this instrument, but they face second‑order effects. If a widespread photoallergen or phototoxic agent is identified in military‑used products, the number of successful claims could increase, raising compensation costs to the Commonwealth (which ultimately are borne by taxpayers). The instrument does not impose liability on manufacturers, but it creates a fact‑finding pathway that may depend on product composition and labelling. Veterans’ advocates and legal aid services are also affected: they must guide clients to obtain evidence matching the factor requirements, which may be difficult where exposure occurred years earlier.

The instrument does not create direct duties on private individuals. Its primary effect is on the rights of claimants and the duties of decision‑makers.

Claimants have the right to have their claim assessed under this SoP if it applies. If they can satisfy at least one factor in section 9 and relate it to their relevant service under section 10, then a reasonable hypothesis is raised. Once raised, the decision‑maker must treat the hypothesis as connecting the condition to service unless the contrary is proved beyond reasonable doubt (under section 120 of the VEA). This is a significant right because the evidentiary threshold for the claimant is low: they need only point to a factor that could be true on the material available, not prove it on the balance of probabilities. The instrument thus strengthens a claimant’s position relative to the Commission.

The Repatriation Commission has a duty to apply the SoP strictly. It cannot accept a hypothesis based on a factor not listed, such as systemic exposure to a phototoxic drug (which is explicitly excluded by subsection 7(2)(c)(iii)). It must also ensure that the factor relates to the person’s relevant service (section 10). For clinical worsening factors (factors 9(3), 9(4), and 9(5)), the SoP imposes an additional condition: these factors apply only where the photocontact dermatitis was suffered or contracted before or during (but did not arise out of) the relevant service, and the factor must materially contribute to the aggravation. This limits the right to claim worsening if the dermatitis first manifested outside of service but was aggravated by service‑related exposure.

Medical professionals who prepare reports for claims have an implicit duty to ensure their diagnoses and opinions address the precise definitions. If a dermatologist uses the term “photocontact dermatitis” loosely, but fails to exclude allergic contact dermatitis or systemic phototoxicity, the report may not meet the evidentiary standard required by the SoP. The dictionary definitions are legally operative.

No duty arises for employers or product suppliers. However, the “inability to obtain appropriate clinical management” factor (factor 9(5)) effectively creates an expectation on the Defence medical system. If a member is diagnosed with photocontact dermatitis and the military fails to provide appropriate care (such as removing the offending agent, prescribing barrier creams, or changing light exposure), that omission can be used to raise a reasonable hypothesis. This is a duty that arises indirectly from the compensation framework, not from a statutory obligation to treat.

This instrument itself does not create any criminal or civil penalties. It is a rule of evidence, not a prohibitory or mandatory code. Enforcement of the legal obligations that stem from it occurs through the normal channels of administrative review and judicial review.

If the Repatriation Commission fails to apply the SoP correctly, a claimant can seek review by the Veterans’ Review Board, then appeal to the Administrative Appeals Tribunal, and ultimately to the Federal Court on questions of law. The remedy is a set‑aside decision, not a fine or prosecution. The instrument does not impose any financial penalty on government or private entities.

There is no enforcement mechanism directed at claimants. If a claimant fraudulently claims that a factor existed (e.g., falsely claiming exposure to fig tree sap within 48 hours), they could be prosecuted under general social security or criminal fraud provisions, but those are found elsewhere in the VEA or the Criminal Code. The SoP itself does not contain penalties for misrepresentation.

The “enforcement” practicalities lie with the Commission’s internal decision‑making processes. The Commission may require medical evidence to substantiate each element: the diagnosis, the identity of the agent, the topical application, the light exposure, and the timing. If evidence is insufficient, the Commission will reject the claim. If the claimant appeals, the tribunal or court will assess whether the decision‑maker correctly applied the SoP. The RMA does not monitor compliance; its role ends with the determination of the instrument.

Because the SoP is a legislative instrument, it is subject to disallowance and scrutiny by the Senate. That is a parliamentary enforcement mechanism, but it is rarely used for RMA instruments. The practical consequence of a failure to comply with the SoP by decision‑makers is the reversal of decisions, which imposes costs on the Commonwealth in terms of both back‑pay and administrative effort. That cost acts as an incentive for the Commission to apply the instrument correctly.

This SoP is made under subsection 196B(2) of the VEA and is part of a broader framework of Statements of Principles covering hundreds of conditions. It operates alongside the “Balance of Probabilities” version of the same condition (likely No. 83 of 2020), which applies to claims where the standard is the higher civil standard. The VEA section 120A provides that a reasonable hypothesis cannot be found unless the SoP criteria are met. The MRCA section 338 contains an equivalent provision. Thus, the SoP effectively displaces any common‑law medical causation tests in these jurisdictions.

The instrument explicitly cross‑references other SoPs in section 11. If a factor in section 9 refers to an injury or disease that is covered by another SoP, then the factors in that other SoP apply. For example, if the phototoxic agent caused a burn that is separately defined as a traumatic injury, the SoP for that injury may be invoked. This prevents fragmentation of the causation analysis.

The definition of photocontact dermatitis excludes conditions that are covered by other SoPs. Allergic contact dermatitis and irritant contact dermatitis are excluded, meaning a claimant diagnosed with those would need to rely on their separate SoPs (e.g., Statement of Principles concerning allergic contact dermatitis). Similarly, systemic phototoxicity (e.g., from an oral medication) is excluded; there may be a separate SoP for drug‑induced photosensitivity, or it may fall under a general injury SoP.

The ICD‑10‑AM code L56.2 is referenced, but the substantive meaning in subsection 7(2) prevails. This means that even if a medical coder assigns a different code, the SoP’s own definition governs. The Tenth Edition of ICD‑10‑AM is specified (effective 1 July 2017), which may create interpretative issues if future editions change the code or classification, but the SoP’s text remains fixed until amended.

The VEA and MRCA themselves govern service definitions, evidentiary standards, and procedural timelines. The SoP is subordinate to those Acts. It does not modify the requirements for lodging claims or the time limits for review. The interaction with state workers’ compensation laws is nil because the SoP applies only to Commonwealth military‑related compensation.

This instrument repeals the Statement of Principles concerning photocontact dermatitis (No. 108 of 2011) made under subsection 196B(2) of the VEA. The 2011 instrument was registered as F2011L01741. The replacement was determined on 30 October 2020 and commenced on 30 November 2020. The RMA reviews and updates SoPs periodically to reflect current medical‑scientific evidence.

No further amendments to this instrument are recorded in the source. Since its commencement, the instrument has remained as originally enacted. It may be amended in the future if medical‑scientific evidence changes (e.g., if new photoallergens are identified, or if the timing windows for photoallergic reactions are revised). The RMA has indicated in its supporting documentation that SoPs are ordinarily reviewed at intervals determined by new research.

The amendment history is important for practitioners because the timing of the claim determines which SoP applies. Claims made before 30 November 2020 would be assessed under the 2011 SoP (unless the new instrument expressly applied to pending claims, which it does not; section 5 says it applies to claims to which sections 120A or 338 apply, meaning claims made on or after the commencement date). The repeal of the 2011 instrument means it no longer applies to new claims. If a previous claim was denied under the 2011 SoP, the new instrument may provide a basis for reconsideration if the factors are now broader, but only if the claim is re‑lodged or the matter is still within appeal rights.

No litigation is mentioned in the instrument itself. However, Statements of Principles are frequently litigated in the veterans’ jurisdiction. The central interpretive question often is whether a factor was satisfied on the facts. For photocontact dermatitis, potential areas of dispute include:

• Whether a substance qualifies as a “phototoxic agent” or “photoallergen” per the dictionary definitions. The examples given are non‑exhaustive, so a claimant must establish that the particular substance falls within the definition of a topical substance capable of producing direct tissue injury (phototoxic) or an immune response (photoallergen) upon light exposure. The burden of proof rests on the claimant to provide medical or scientific evidence.

• The meaning of “topical” - the definition of phototoxic agent says “topical substance”. If a substance was applied systemically (e.g., an injected drug that reaches the skin via circulation), it is not a phototoxic agent for the purposes of this SoP, and the factor cannot be met. The definition of photoallergen does not include the word “topical”, but the factor in section 9(2) requires the area of skin to be exposed to light “in the presence of a photoallergen”. The note says the initial sensitising exposure may be systemic, but the re‑exposure factor requires the photoallergen to be present in the affected skin. This distinction has been examined in tribunal decisions regarding ketoprofen gel versus oral ketoprofen.

• The timing windows (48 hours for phototoxic, five days for photoallergic) are strict. Claimants often have difficulty proving the exact window, especially for historical exposures. The Federal Court has, in other SoP contexts, considered whether “within the 48 hours before the clinical onset” means the exposure must occur before the onset of the specific episode of dermatitis, not the first ever episode. That can be critical for worsening claims.

• Factor 9(5) (inability to obtain appropriate clinical management) is a common source of litigation because “appropriate” is not defined. Tribunals have considered whether the management was actually available, whether the claimant sought it, and whether any failure caused a worsening.

• The relationship to service requirement (section 10) ensures that even if a factor exists, it must be causally related to the person’s relevant service. For example, if a veteran’s photocontact dermatitis was caused by a recreational activity on leave using a civilian cosmetic product, the factor may exist but not be service‑related.

Several traps await the unwary practitioner or claimant.

Narrow time windows. Factor 9(1) requires exposure to the phototoxic agent within the 48 hours before clinical onset. For photoallergic contact dermatitis, the window is five days. If the claimant cannot pinpoint the precise onset or the date of last exposure, the claim will fail. The note in factor 9(2) states that the initial sensitising exposure to a photoallergen may have occurred months to years earlier, but the re‑exposure must still be within the five days. Claimants may mistakenly think that a distant prior exposure suffices.

Topical application mandatory for phototoxic. The definition of “phototoxic agent” explicitly requires it to be a “topical substance”. The exclusion in section 7(2)(c)(iii) confirms that phototoxic contact dermatitis due to systemic administration of a phototoxicant is not covered by this SoP. This means that if a person took a phototoxic drug orally (e.g., tetracyclines, fluoroquinolones, some diuretics) and got a sunburn, the claim cannot rely on this SoP. The claimant would need to find another SoP (e.g., a general injury SoP or a drug‑induced photosensitivity SoP if one exists). Similarly, for photoallergens, the initial sensitisation can be systemic, but the factor itself requires the skin to be exposed to light in the presence of a photoallergen. If the photoallergen is ingested and reaches the skin via the bloodstream, the presence in the skin is still present, but the wording of the factor (“in the presence of a photoallergen”) may not require topical application. However, the safer reading is that the photoallergen must be present on or in the skin at the time of light exposure.

Exclusions of common dermatitis types. Allergic contact dermatitis and irritant contact dermatitis are excluded. If the diagnosis is not specifically photocontact dermatitis but just “dermatitis”, the claim may be redirected to another SoP. Claimants should ensure a dermatologist explicitly uses the term “photocontact dermatitis” and distinguishes the other types.

Relevant service definition is restrictive. Not all defence service counts. Only operational service, peacekeeping service, hazardous service, British nuclear test defence service (under VEA), and warlike/non‑warlike service (under MRCA) qualify. A person who served in a non‑hazardous, non‑operational capacity during peacetime (e.g., a cook in a barracks) may not have relevant service, even if they developed photocontact dermatitis from exposure to cleaning chemicals in the kitchen. This is a common oversight.

Compliance with this instrument is not about obeying a regulatory rule but about navigating the compensation claim process. The following practical steps apply to different actors.

For claimants and their representatives:

1. Obtain a definitive diagnosis. A dermatologist should diagnose photocontact dermatitis and expressly rule out allergic contact dermatitis, irritant contact dermatitis, and systemic phototoxicity. The diagnosis should specify whether it is phototoxic or photoallergic, as the time windows differ.

2. Identify the agent. The claimant must identify the specific topical phototoxic agent or photoallergen that was on the affected skin at the time of light exposure. This may require a history of product use (sunscreens, cosmetics, NSAID gels, lime juice, fig tree sap, coal tar preparations) or work‑related chemicals. Photo‑patch testing may be needed for photoallergic cases. Document the brand, ingredients, and application site.

3. Time the exposure. For phototoxic onset, show that the agent was applied to the affected skin within 48 hours before the dermatitis began. For photoallergic onset, the period is five days. Keep a diary if possible, or rely on contemporaneous medical records. For worsening, the same windows apply to the episode of worsening.

4. Prove light exposure. Light includes sunlight, but also artificial UV lamps, operating theatre lights, and therapy lamps. The exposure must have occurred while the agent was present on the skin. Note that light through glass windows counts.

5. Establish relevant service. The claim must fall within one of the categories of relevant service defined in the Schedule. Provide evidence of the period and type of service (e.g., operational service in a combat zone, hazardous service from exposure to chemicals). If the service is not on the list, no claim under this SoP.

6. Consider the clinical management factor. If exposure evidence is weak, investigate whether appropriate clinical management was unavailable. This requires evidence that the Defence medical system failed to diagnose, treat, or advise on avoidance of light or the offending agent. A medical report stating that the claimant was not given proper instructions or that treatment was delayed may suffice.